SI1644384T1 - Postopek in intermediati za sintezo entekavirja - Google Patents

Postopek in intermediati za sintezo entekavirja

Info

Publication number
SI1644384T1
SI1644384T1 SI200332236T SI200332236T SI1644384T1 SI 1644384 T1 SI1644384 T1 SI 1644384T1 SI 200332236 T SI200332236 T SI 200332236T SI 200332236 T SI200332236 T SI 200332236T SI 1644384 T1 SI1644384 T1 SI 1644384T1
Authority
SI
Slovenia
Prior art keywords
entecavir
intermediates
synthesis
Prior art date
Application number
SI200332236T
Other languages
English (en)
Slovenian (sl)
Inventor
Yadagiri R. Pendri
Chung-Pin H. Chen
Sunil S. Patel
Jeffrey M. Evans
Jing Liang
David R. Kronenthal
Gerald L. Powers
Siva Josyula Prasad
Jeffrey T. Bien
Zhongping Shi
Ramesh N. Patel
Yeung Y. Chan
Sushil K. Rijhwani
Ambarish K. Singh
Shaopeng Wang
Milan Stojanovic
Richard Polniaszek
Charles Lewis
John Thottathil
Dhileepkumar Krishnamurty
Maotang X. Zhou
Purushotham Vemishetti
Amit Banerjee
David J. Kucera
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI1644384T1 publication Critical patent/SI1644384T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0825Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083Syntheses without formation of a Si-C bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0825Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/0827Syntheses with formation of a Si-C bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200332236T 2002-12-11 2003-12-10 Postopek in intermediati za sintezo entekavirja SI1644384T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43254902P 2002-12-11 2002-12-11
EP03812974A EP1644384B1 (en) 2002-12-11 2003-12-10 Process and intermediates for the synthesis of entecavir
PCT/US2003/039554 WO2004052310A2 (en) 2002-12-11 2003-12-10 Process and intermediates for synthesis entecavir

Publications (1)

Publication Number Publication Date
SI1644384T1 true SI1644384T1 (sl) 2013-02-28

Family

ID=32507962

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332236T SI1644384T1 (sl) 2002-12-11 2003-12-10 Postopek in intermediati za sintezo entekavirja

Country Status (18)

Country Link
US (3) US7034152B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2433941A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4726491B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101096830B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (6) CN101899063B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003300884B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR122019020833B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2735485A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1644384T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2397104T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL168691A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (3) IN2012DN00606A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05005971A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL397715A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1644384E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1644384T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI327568B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004052310A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002990A2 (en) * 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
IN2012DN00606A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2002-12-11 2015-06-12 Bristol Mayers Squibb Company
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (zh) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 恩替卡韦的制备方法
CN1699366A (zh) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 嘌呤衍生物
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101863842B (zh) * 2006-08-24 2012-02-01 江苏正大天晴药业股份有限公司 恩替卡韦中间体及合成方法
CN101130542B (zh) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 抗病毒核苷类似物的合成方法
CN101838207B (zh) * 2006-08-24 2012-04-25 江苏正大天晴药业股份有限公司 恩替卡韦的中间体及合成方法
CN101838270B (zh) * 2006-08-24 2012-04-18 江苏正大天晴药业股份有限公司 恩替卡韦的中间体及制备
EP2078054A1 (en) * 2006-10-30 2009-07-15 Pirelli Tyre S.p.A. Tire for vehicle wheels comprising crosslinked elastomeric composition
CN101245068A (zh) 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101371841A (zh) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 结晶型恩替卡韦制剂及其制备方法和应用
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101074217B (zh) * 2007-04-04 2010-11-24 北京精华耀邦医药科技有限公司 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法
CN101397333A (zh) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
CN101723945B (zh) * 2008-10-17 2011-11-02 上海清松制药有限公司 一种制备抗病毒药物恩替卡韦中间体的方法
KR101150254B1 (ko) * 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
CN101828693B (zh) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 制备低粘度高流动性类胡萝卜素油悬浮液的方法及其应用
CN101531660B (zh) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 一种恩替卡韦一水合物的工业化生产工艺
KR101301200B1 (ko) * 2009-10-12 2013-09-06 한미사이언스 주식회사 엔테카비르의 신규한 제조방법 및 이에 사용되는 중간체
CN101693713B (zh) * 2009-10-28 2011-11-09 福建广生堂药业有限公司 一种恩替卡韦的晶型及其制备方法和药物应用
CN101781301B (zh) * 2010-01-15 2013-04-10 复旦大学 一种制备恩替卡韦的方法
US8481728B2 (en) 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
CN101805339B (zh) * 2010-04-12 2012-01-11 王明 一种制备恩替卡韦化合物的方法
CA2705953C (en) * 2010-05-31 2018-05-01 Alphora Research Inc. Carbanucleoside synthesis and intermediate compounds useful therein
CN101891741B (zh) * 2010-07-06 2013-01-23 苏州汉德森医药科技有限公司 抗病毒药恩替卡韦的新合成工艺
CN106928227B (zh) 2010-07-15 2020-06-30 浙江奥翔药业股份有限公司 恩替卡韦的合成方法及其中间体化合物
TWI668220B (zh) * 2010-08-30 2019-08-11 浙江奧翔藥業股份有限公司 恩替卡韋的合成方法及其中間體化合物
KR101269491B1 (ko) * 2010-12-23 2013-05-31 주식회사 한서켐 엔테카비어 제조방법
EP2474548A1 (en) 2010-12-23 2012-07-11 Esteve Química, S.A. Preparation process of an antiviral drug and intermediates thereof
CN102225938A (zh) * 2011-04-25 2011-10-26 海南卫康制药(潜山)有限公司 恩替卡韦一水合物新合成工艺
CN102267875B (zh) * 2011-06-17 2013-04-24 常州寅盛药业有限公司 一种恩替卡韦中间体的制备方法
CN102952156A (zh) * 2011-08-29 2013-03-06 南京工业大学 一种抗乙肝药物恩替卡韦中间体及其合成
CN102952135B (zh) * 2011-08-31 2015-04-08 南京工业大学 一种乙肝药物恩替卡韦的合成方法
EP2597096A1 (en) 2011-11-24 2013-05-29 Esteve Química, S.A. Process for preparing entecavir and intermediates thereof
CN103304375B (zh) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 恩替卡韦的合成中间体及其制备方法
US9908840B2 (en) 2012-10-02 2018-03-06 California Institute Of Technology Reactions of aromatic substrates with base-activated hydrosilanes-silylations and reductive cleavage
RU2651570C2 (ru) 2012-10-02 2018-04-23 Кэлифорниа Инститьют Оф Текнолоджи Силилирование ароматических соединений без переходных металлов
CN104017014A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法,以及中间体
CN104016984A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一种恩替卡韦及其中间体的制备方法,以及中间体
CN104017015B (zh) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法,以及中间体
CN104017016B (zh) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法,以及中间体
CN104017012A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法,以及中间体
CN104177396A (zh) * 2013-05-23 2014-12-03 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN104177397B (zh) * 2013-05-23 2017-10-13 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN104177394B (zh) * 2013-05-23 2017-12-05 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
CA2955546C (en) 2014-08-06 2022-12-13 California Institute Of Technology Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
KR101640503B1 (ko) 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 개선된 제조방법
KR101640504B1 (ko) 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 제조방법
CN105037363B (zh) * 2015-07-13 2016-08-24 山东罗欣药业集团股份有限公司 一种恩替卡韦化合物的新合成方法
KR102351734B1 (ko) * 2016-04-07 2022-01-14 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 2'-플루오로-6'-메틸렌-탄소환식 아데노신(fmca) 및 2'-플루오로-6'-메틸렌-탄소환식 구아노신(fmcg)의 합성
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
CN107163049B (zh) * 2017-05-31 2019-06-18 湖北远大生命科学与技术有限责任公司 一种恩替卡韦的制备方法
WO2019080686A1 (zh) * 2017-10-26 2019-05-02 广州市朗启医药科技有限责任公司 恩替卡韦中间体及其合成方法以及恩替卡韦的合成方法
CN109705063B (zh) 2017-10-26 2021-01-01 广州市朗启医药科技有限责任公司 恩替卡韦中间体及其合成方法以及恩替卡韦的合成方法
CN109232637B (zh) * 2018-10-29 2020-11-24 常州博海威医药科技股份有限公司 一种恩替卡韦中间体的制备方法
CN109593090A (zh) * 2019-01-25 2019-04-09 连云港贵科药业有限公司 一种恩替卡韦的合成方法
CN113831341B (zh) * 2020-06-08 2025-06-10 连云港润众制药有限公司 一种恩替卡韦的制备方法
CN112625041A (zh) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 恩替卡韦的新制备方法以及中间体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594439A (en) 1980-08-06 1986-06-10 The Board Of Trustees Of The Leland Stanford Jr. University Method for asymmetric epoxidation
US4471130A (en) 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
US4900847A (en) 1985-04-04 1990-02-13 Massachusetts Institute Of Technology Catalytic asymmetric epoxidation
JPH01207257A (ja) * 1988-02-15 1989-08-21 Nippon Oil & Fats Co Ltd α−リノレン酸の分離法
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
EP0630897A3 (en) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
US5665890A (en) * 1995-03-14 1997-09-09 President And Fellows Of Harvard College Stereoselective ring opening reactions
WO1998009964A1 (en) * 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
US6127159A (en) * 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
SK288008B6 (sk) * 2000-02-29 2012-10-02 Bristol-Myers Squibb Company Pharmaceutical composition for use in the treatment of hepatitis B virus infection or co-infection
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
BR0110023A (pt) * 2000-04-13 2003-12-30 Pharmasset Ltd Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
IN2012DN00606A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2002-12-11 2015-06-12 Bristol Mayers Squibb Company
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Also Published As

Publication number Publication date
CN100379746C (zh) 2008-04-09
IN2012DN00604A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-08-21
IL168691A (en) 2011-09-27
TW200504065A (en) 2005-02-01
US7034152B2 (en) 2006-04-25
ES2397104T3 (es) 2013-03-04
PT1644384E (pt) 2013-01-23
CN101130552B (zh) 2010-07-28
CA2508811C (en) 2014-11-18
US20060106216A1 (en) 2006-05-18
IN2012DN00606A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12
BR122019020833B8 (pt) 2021-07-27
PL212790B1 (pl) 2012-11-30
BR122019020833B1 (pt) 2020-09-01
CN1747959A (zh) 2006-03-15
AU2003300884A1 (en) 2004-06-30
KR20090084979A (ko) 2009-08-05
KR100944063B1 (ko) 2010-02-24
CN104788485B (zh) 2017-10-03
IN2012DN00605A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12
CN101899063A (zh) 2010-12-01
CA2508811A1 (en) 2004-06-24
EP1644384B1 (en) 2012-10-31
KR101096830B1 (ko) 2011-12-22
JP4726491B2 (ja) 2011-07-20
US20060106215A1 (en) 2006-05-18
PL377263A1 (pl) 2006-01-23
EP2433941A1 (en) 2012-03-28
US7550619B2 (en) 2009-06-23
WO2004052310A2 (en) 2004-06-24
DK1644384T3 (da) 2013-02-11
JP2010222365A (ja) 2010-10-07
AU2003300884B2 (en) 2010-01-21
CN102675355A (zh) 2012-09-19
CN101899063B (zh) 2012-12-12
JP2006509800A (ja) 2006-03-23
PL397715A1 (pl) 2012-03-26
CN101130552A (zh) 2008-02-27
US20040192912A1 (en) 2004-09-30
BRPI0317255B8 (pt) 2021-05-25
KR20050087831A (ko) 2005-08-31
BR0317255A (pt) 2005-11-08
MXPA05005971A (es) 2005-12-05
EP1644384A4 (en) 2009-09-02
WO2004052310A3 (en) 2005-03-03
TWI327568B (en) 2010-07-21
BRPI0317255B1 (pt) 2019-12-24
CN102675355B (zh) 2015-05-06
CA2735485A1 (en) 2004-06-24
US7541460B2 (en) 2009-06-02
CN101130543A (zh) 2008-02-27
CN104788485A (zh) 2015-07-22
CN101130543B (zh) 2011-06-08
EP1644384A2 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
SI1644384T1 (sl) Postopek in intermediati za sintezo entekavirja
IL214165A0 (en) Intermediates useful in the synthesis of statin derivatives
IL223579A0 (en) Synthesis of amines and intermediates for the synthesis thereof
HUP0500851A3 (en) Process for the preparation of rosuvastatin
SI1476162T1 (sl) Nadzirana sinteza ziprasidona
PT1840125E (pt) Intermediários para a produção de dioxano-2-alquilcarbamatos
PT1664061T (pt) Processo para a síntese de compostos de morfinano e seus intermediários
AU2003253188A8 (en) Novel processes and intermediates for preparing triazolo-pyridines
GB0222909D0 (en) Novel process and intermediates
GB0222912D0 (en) Novel process and intermediates
SI1403264T1 (en) Process for the industrial synthesis of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxydimethylester
AU2003242867A8 (en) Process for the synthesis of mosapride
PL373627A1 (en) Process for the preparation of melamine
AU2003210629A1 (en) Methods for the integrated synthesis and purification of oligonucleotides
PL371583A1 (en) Process for the preparation of 7alpha-methylsteroids
AU2003278420A8 (en) Process for the preparation of ganciclovir
SG111997A1 (en) Improved process for the preparation of polyalkylphenoxyaminoalkanes
AU2003224327A8 (en) Process for the synthesis of peptides
IL164788A0 (en) Process for the preparation of 3-isochromanone
PL375437A1 (en) Synthesis of gatifloxacin
GB0225106D0 (en) Synthesis of 3 hydroxy-5 -steroids
HK1082740A (en) Process and intermediates for synthesis entecavir
PL373972A1 (en) Process for the preparation of morpholine derivatives and intermediates therefore
AU2003217354A8 (en) Synthesis of sulfamidates
AU2003226717A8 (en) Intermediates for the synthesis of discodermolide and related analogues and methods for their preparation